These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1730 related articles for article (PubMed ID: 33932547)

  • 21. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.
    Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS
    Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
    Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
    mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes.
    Guo H; Hu BJ; Yang XL; Zeng LP; Li B; Ouyang S; Shi ZL
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32699095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis.
    Kotani N; Nakano T; Kuwahara R
    J Biol Chem; 2022 Nov; 298(11):102500. PubMed ID: 36152751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Corilagin and 1,3,6-Tri-
    Binette V; Côté S; Haddad M; Nguyen PT; Bélanger S; Bourgault S; Ramassamy C; Gaudreault R; Mousseau N
    Phys Chem Chem Phys; 2021 Jul; 23(27):14873-14888. PubMed ID: 34223589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
    Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
    Tai W; He L; Zhang X; Pu J; Voronin D; Jiang S; Zhou Y; Du L
    Cell Mol Immunol; 2020 Jun; 17(6):613-620. PubMed ID: 32203189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.
    Liu J; Chen X; Liu Y; Lin J; Shen J; Zhang H; Yin J; Pu R; Ding Y; Cao G
    Infect Dis Poverty; 2021 Aug; 10(1):112. PubMed ID: 34419160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Cellular Entry Is Independent of the ACE2 Cytoplasmic Domain Signaling.
    Karthika T; Joseph J; Das VRA; Nair N; Charulekha P; Roji MD; Raj VS
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
    Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2.
    Li C; Zhou H; Guo L; Xie D; He H; Zhang H; Liu Y; Peng L; Zheng L; Lu W; Mei Y; Liu Z; Huang J; Wang M; Shu D; Ding L; Lang Y; Luo F; Wang J; Huang B; Huang P; Gao S; Chen J; Qian CN
    J Transl Med; 2022 Jul; 20(1):314. PubMed ID: 35836239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor.
    Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS
    J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
    Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
    Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an
    Pandey P; Rane JS; Chatterjee A; Kumar A; Khan R; Prakash A; Ray S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6306-6316. PubMed ID: 32698689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies.
    Durdagi S; Avsar T; Orhan MD; Serhatli M; Balcioglu BK; Ozturk HU; Kayabolen A; Cetin Y; Aydinlik S; Bagci-Onder T; Tekin S; Demirci H; Guzel M; Akdemir A; Calis S; Oktay L; Tolu I; Butun YE; Erdemoglu E; Olkan A; Tokay N; Işık Ş; Ozcan A; Acar E; Buyukkilic S; Yumak Y
    Mol Ther; 2022 Feb; 30(2):963-974. PubMed ID: 34678509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein.
    Wang L; Wu Y; Yao S; Ge H; Zhu Y; Chen K; Chen WZ; Zhang Y; Zhu W; Wang HY; Guo Y; Ma PX; Ren PX; Zhang XL; Li HQ; Ali MA; Xu WQ; Jiang HL; Zhang LK; Zhu LL; Ye Y; Shang WJ; Bai F
    Acta Pharmacol Sin; 2022 Apr; 43(4):788-796. PubMed ID: 34349236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.